BACKGROUND: Chordomas are rare and indolent bone tumors that arise in the skull base and mobile spine. Distant metastases occur in >20% of cases, but morbidity and mortality are mainly related to local relapses that affect the majority of patients. Standard chemotherapy has modest activity, whereas new targeted therapies (alone or in combination) have some activity in controlling disease progression. However, the scarcity of preclinical models capable of testing in vivo responses to these therapies hampers the development of new medical strategies. METHODS: In this study, 8 chordoma samples taken from 8 patients were implanted in nude mice. Four engrafted successfully and gave rise to tumor masses that were analyzed histologically, by means of fluorescence in situ hybridization and biochemical techniques. The data relating to each of the mouse tumors were compared with those obtained from the corresponding human tumor. RESULTS: All 4 engraftments retained the histological, genetic and biochemical features of the human tumors they came from. In one epidermal growth factor receptor(EGFR)-positive xenograft, responsiveness to lapatinib was evaluated by comparing the pre- and post treatment findings. The treatment induced a low-level, heterogeneous switching off of EGFR and its downstream signaling effectors. CONCLUSIONS: Overall, this model is very close to human chordoma and represents a new means of undertaking preclinical investigations and developing tailored therapies.
BACKGROUND:Chordomas are rare and indolent bone tumors that arise in the skull base and mobile spine. Distant metastases occur in >20% of cases, but morbidity and mortality are mainly related to local relapses that affect the majority of patients. Standard chemotherapy has modest activity, whereas new targeted therapies (alone or in combination) have some activity in controlling disease progression. However, the scarcity of preclinical models capable of testing in vivo responses to these therapies hampers the development of new medical strategies. METHODS: In this study, 8 chordoma samples taken from 8 patients were implanted in nude mice. Four engrafted successfully and gave rise to tumor masses that were analyzed histologically, by means of fluorescence in situ hybridization and biochemical techniques. The data relating to each of the mousetumors were compared with those obtained from the corresponding humantumor. RESULTS: All 4 engraftments retained the histological, genetic and biochemical features of the humantumors they came from. In one epidermal growth factor receptor(EGFR)-positive xenograft, responsiveness to lapatinib was evaluated by comparing the pre- and post treatment findings. The treatment induced a low-level, heterogeneous switching off of EGFR and its downstream signaling effectors. CONCLUSIONS: Overall, this model is very close to humanchordoma and represents a new means of undertaking preclinical investigations and developing tailored therapies.
Authors: Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm Journal: Nat Med Date: 2011-10-23 Impact factor: 53.440
Authors: Taru Muranen; Laura M Selfors; Devin T Worster; Marcin P Iwanicki; Loling Song; Fabiana C Morales; Sizhen Gao; Gordon B Mills; Joan S Brugge Journal: Cancer Cell Date: 2012-02-14 Impact factor: 31.743
Authors: Elena Tamborini; Francesca Miselli; Tiziana Negri; M Stefania Lagonigro; Samantha Staurengo; Gian Paolo Dagrada; Silvia Stacchiotti; Elisa Pastore; Alessandro Gronchi; Federica Perrone; Antonino Carbone; Marco A Pierotti; Paolo G Casali; Silvana Pilotti Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Dhara N Amin; Natalia Sergina; Deepika Ahuja; Martin McMahon; Jimmy A Blair; Donghui Wang; Byron Hann; Kevin M Koch; Kevan M Shokat; Mark M Moasser Journal: Sci Transl Med Date: 2010-01-27 Impact factor: 17.956
Authors: Roberta Frapolli; Elena Tamborini; Emanuela Virdis; Ezia Bello; Eva Tarantino; Sergio Marchini; Federica Grosso; Roberta Sanfilippo; Alessandro Gronchi; Juan Carlos Tercero; Gabriella Peloso; Paolo Casali; Silvana Pilotti; Maurizio D'Incalci Journal: Clin Cancer Res Date: 2010-08-20 Impact factor: 12.531
Authors: Silvia Stacchiotti; Paolo Giovanni Casali; Salvatore Lo Vullo; Luigi Mariani; Elena Palassini; Mario Mercuri; Marco Alberghini; Silvana Pilotti; Licciana Zanella; Alessandro Gronchi; Piero Picci Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: Joseph H Schwab; Patrick J Boland; Narasimhan P Agaram; Nicholas D Socci; Tianhua Guo; Gary C O'Toole; Xinhui Wang; Elena Ostroumov; Christopher J Hunter; Joel A Block; Stephen Doty; Soldano Ferrone; John H Healey; Cristina R Antonescu Journal: Cancer Immunol Immunother Date: 2008-07-19 Impact factor: 6.968
Authors: Elena Tamborini; Emanuela Virdis; Tiziana Negri; Marta Orsenigo; Silvia Brich; Elena Conca; Alessandro Gronchi; Silvia Stacchiotti; Giacomo Manenti; Paolo G Casali; Marco A Pierotti; Silvana Pilotti Journal: Neuro Oncol Date: 2010-02-17 Impact factor: 12.300
Authors: A Alholle; A T Brini; J Bauer; S Gharanei; S Niada; A Slater; D Gentle; E R Maher; L Jeys; R Grimer; V P Sumathi; F Latif Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: John Henry Owen; Christine M Komarck; Anthony C Wang; Waleed M Abuzeid; Richard F Keep; Erin L McKean; Stephen Sullivan; Xing Fan; Mark E P Prince Journal: J Neurosurg Date: 2017-04-21 Impact factor: 5.115
Authors: Ahmad Al Shihabi; Ardalan Davarifar; Huyen Thi Lam Nguyen; Nasrin Tavanaie; Scott D Nelson; Jane Yanagawa; Noah Federman; Nicholas Bernthal; Francis Hornicek; Alice Soragni Journal: Sci Adv Date: 2022-02-16 Impact factor: 14.136
Authors: Tianna Zhao; I-Mei Siu; Tara Williamson; Haoyu Zhang; Chenchen Ji; Peter C Burger; Nick Connis; Jacob Ruzevick; Menghang Xia; Lucia Cottone; Adrienne M Flanagan; Christine L Hann; Gary L Gallia Journal: J Pathol Date: 2021-07-28 Impact factor: 9.883